|
USA-NY-ADAMS BASIN Azienda Directories
|
Azienda News:
- Lilly to acquire Verve Therapeutics to advance one-time . . .
INDIANAPOLIS, June 17, 2025 PRNewswire -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve
- Eli Lilly strikes deal to buy Crispr gene-editing biotech Verve
Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1 3bn, the latest acquisition by the world’s most valuable drugmaker as it seeks to boost its
- Lilly to acquire Verve in $1B bet on gene editing for heart . . .
Eli Lilly agreed to buy Verve Therapeutics for $1 billion, betting on the promise of one-and-done gene therapies to treat cardiovascular disease The deal announced Tuesday offers Verve stockholders $10 50 a share, plus a contingent value right worth another $3 a share
- Eli Lilly to acquire Verve Therapeutics for $1. 3 billion
Lilly has struck multiple partnership deals with gene-editing companies in the last two years to expand its portfolio beyond its weight-loss and diabetes drugs
- Lilly to Acquire Verve Therapeutics for Up to $1. 3B
Eli Lilly has agreed to acquire Verve Therapeutics for up to $1 3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led
- Eli Lilly to buy gene-editing biotech Verve for up to $1. 3 . . .
Eli Lilly said Tuesday that it will acquire Verve Therapeutics, Lilly will acquire Verve for $10 50 per share, a premium of nearly 70% to the biotech’s share price at Monday’s close
- Eli Lilly to acquire Verve Therapeutics for up to $1. 3B - Axios
By the numbers: Lilly is paying $10 50 per share, or about $1 billion, in cash for Verve, representing a 113% premium to Verve's 30-day volume-weighted average stock price that ended Monday But Lilly also offered a contingent value right (CVR) worth up to an additional $3 per share that would boost the total deal value to $1 3 billion
- Lilly to Buy US Biotech Verve for $1. 3 Billion - Bloomberg
Eli Lilly Co agreed to buy Verve Therapeutics Inc , a US biotech that’s seeking to use gene editing to prevent clogged arteries, for up to $1 3 billion in the obesity drug maker’s latest
- Eli Lilly to Acquire Verve Therapeutics for Up to $1. 3 Billion
By Connor Hart Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio
- Eli Lilly to Acquire Gene-Editing Therapy Developer Verve . . .
Eli Lilly to Acquire Gene-Editing Therapy Developer Verve Therapeutics for up to $1 3 Billion, Companies Say The logo of Lilly is seen on a wall of the Lilly France company unit, part of the
|
|